Read Dr. Eshaghian’s Article In Paact
ON THE HORIZON – INDIVIDUALIZED BIOMARKER DRIVEN THERAPY IN CASTRATE RESISTANT PROSTATE CANCER (CRPC) –
We are pleased to announce that Provenge®(sipuleucel-T), a breakthrough treatment for certain types of advanced prostate cancer, is now available at Compassionate Oncology Medical Group. Provenge is the first and only immunotherapy approved by the FDA for the treatment of asymptomatic or minimally symptomatic metastatic, castrate-resistant (hormone-refractory) prostate cancer. Continue Reading
You Might Also Enjoy...
ON THE HORIZON – INDIVIDUALIZED BIOMARKER DRIVEN THERAPY IN CASTRATE RESISTANT PROSTATE CANCER (CRPC) –
Dr. Eshaghian will update us on what is fact and what is fiction when treating high risk and/or metastatic PCa. Dr. Bob will update us on ‘Challenging Prostate Cancer Treatment Biases; Is Nothing Sacred?”
Watch Dr. Bob & Dr. Eshaghian’s latest lecture, titled “Our Three-Pronged Approach Protocol for treatment of high-risk metastatic and/or recurrent prostate cancer and results from hundreds of PC patients utilizing High-Dose Testosterone Replacement...
See the latest PAACT newsletter (March 2014) to read Dr. Bob’s article: “Challenging PC Treatment Biases – Is Nothing Sacred? – Part I”. This is part of a three issue series, starting with an article in the Winter 2013 issue of PAACT titled...
See the latest PAACT newsletter (Dec 2013) to read Dr. Bob’s article: “Dr. Bob’s treatments and insights regarding prostate cancer”. Click here to download a copy for free. For more information on PAACT...
Dr. Bob, Dr. Eshaghian and the COMG staff wishes all a Happy Hanukkah, Merry Christmas, and a Happy HEALTHY New Year and Year of the Horse.